Australian biotech, Novartis in pact to block transplant rejection

06/5/2006 | Age (Melbourne, Australia), The

Possibly Australia's largest joint drug development deal -- worth up to $287 million -- has been signed between the biotech Cytopia and Novartis to produce products to prevent rejection of transplanted organs. Under the deal, Cytopia will develop drugs that inhibit the JAK3 enzyme from hyperactivating the immune system and causing rejection.

View Full Article in:

Age (Melbourne, Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN